Le Lézard
Classified in: Health
Subjects: WOM, FVT

Duchesnay Inc. to Present a Poster on Ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS)


BLAINVILLE, QC, Sept. 13, 2018 /PRNewswire/ - Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

Logo: Duchesnay Inc. (CNW Group/Duchesnay inc.)

The abstract titled: Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate Vulvar Health from Photograph Images Taken at Investigative Sites of Consenting Subjects Participating in the Efficacy and Safety of Ospemifene in Patients with Moderate to Severe Vaginal Dryness, a Symptom of Vulvovaginal Atrophy (VVA) due to Menopause, will be presented as a poster presentation on October 4, 2018, from 6:00 to 7:00 p.m. PST.

This poster will include new data related to the use of ospemifene in menopausal women with moderate to severe vaginal dryness, a symptom of vulvovaginal atrophy (VVA), a part of the genitourinary syndrome of menopause (GSM). Duchesnay is currently seeking marketing authorization for this additional indication for ospemifene and this new safety and efficacy data is currently under evaluation by the United States Food and Drug Administration.

"We are proud to share new data on ospemifene for the treatment of vaginal dryness, a frequent and most bothersome symptom of VVA, which is a component of the genitourinary syndrome of menopause," said Graziella Soulban, Senior Director of Medical Affairs at Duchesnay. "This data, based on visual vulvovaginal evaluations, enhances the understanding of how ospemifene can improve vulvovaginal health in post-menopausal women."

About Duchesnay
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, visit www.DuchesnayUSA.com.

 

SOURCE Duchesnay inc.


These press releases may also interest you

at 06:35
Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2024. "Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our...

at 06:35
Sage Therapeutics, Inc. , a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024. "The launch of ZURZUVAE is off to...

at 06:30
Sage Veterinary Imaging (SVI) has welcomed Peter Selover to its team as president and chief operating officer. Selover had previously served as chief executive officer of Exubrion Therapeutics....

at 06:14
The Hong Kong Polytechnic University (PolyU) is partnering with ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, to expand the global impact and speed up the market penetration of PolyU's...

at 06:09
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Digital Personalized Nutrition Market ? (By Purchase Model (Subscription, One Time Purchase), By End-users (Direct Consumers, Wellness & Fitness Centers,...

at 06:05
Global nonprofit BrightFocus Foundation announces $10 million in new Alzheimer's disease, macular degeneration, and glaucoma research grant funding?age-related diseases with no cure that affect more than 335 million people worldwide. This year's...



News published on and distributed by: